tbuckley/cabot-search huggingface dataset:
Survival After Coronary Artery Bypass Grafting in Patients With Preoperative Heart Failure and Preserved vs Reduced Ejection Fraction
Authors: Magnus Dalén, Lars H. Lund, Torbjörn Ivert, Martin J. Holzmann, Ulrik Sartipy
Journal: JAMA Cardiology (2016)

Data on the prognostic consequence of heart failure (HF) with preserved ejection fraction in patients undergoing coronary artery bypass grafting (CABG) are limited and inconclusive.To investigate the survival after CABG in patients with preoperative HF and preserved ejection fraction (pEF) vs reduced ejection fraction (rEF).Swedish nationwide population-based cohort study that included all patients who underwent primary isolated CABG between January 1, 2001, and December 31, 2013, from the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) register, with follow-up for all-cause mortality in March 2014. Information regarding baseline characteristics, all-cause mortality, and readmissions for HF was obtained from national health data registers. Preserved EF was defined as at least 50%.The primary outcome was all-cause mortality. A secondary outcome measure was a combination of all-cause mortality and readmission for HF.The study included 41 906 patients, 37 234 without known HF (27 165 with pEF and 10 069 with rEF) and 4672 with HF (1216 with pEF and 3456 with rEF). Their mean (SD) age was 67.4 (9.3) years, and 21.0% were female. During a mean (SD) follow-up time of 6.0 (3.3) years, 19.0% (7943 of 41 906) of patients died, including 13.2% (3574 of 27 165) with no HF and pEF, 24.6% (2476 of 10 069) with no HF and rEF, 33.9% (412 of 1216) with HFpEF, and 42.9% (1481 of 3456) with HFrEF. The multivariable-adjusted hazard ratios for death were 1.47 (95% CI, 1.40-1.56), 1.62 (95% CI, 1.46-1.80), and 2.29 (95% CI, 2.14-2.44) in patients with no HF and rEF, patients with HFpEF, and patients with HFrEF compared with patients with no HF and pEF. The findings were similar for the combined outcome of all-cause mortality and readmission for HF. The multivariable-adjusted hazard ratios for death within 30 days of surgery were 2.25 (95% CI, 1.86-2.73), 1.83 (95% CI, 1.26-2.66), and 2.52 (95% CI, 1.99-3.19) in patients with no HF and rEF, patients with HFpEF, and patients with HFrEF.A history of HF was an important risk factor for poor short-term and long-term outcomes after CABG regardless of preoperative EF. Reduced EF more than doubled the risk of early death after CABG.
Grosvenor Charles Thomas Burfitt-Williams
Authors: Alfred W Wechsler
Journal: BMJ (2016)

Grosvenor Charles Thomas Burfitt-Williams was born in Sydney, Australia. Both his parents were doctors and his mother was one of the first woman doctors in Australia. He was the eldest of three boys, all of whom studied medicine.

“Burf,” as he was affectionately known, graduated from Sydney …
Ultrasound-guided core needle biopsy (US-CNB) of superficial lymph nodes: An alternative to fine-needle aspiration cytology (FNAC) for the diagnosis of lymph node metastasis in melanoma.
Authors: Gerome Bohelay, Maxime Battistella, Cécile Pagès, Nicole Basset-Seguin, Manuelle Viguier, Delphine Kerob, Nika Madjlessi, Michel Baccard, Christelle Comte, Alain Archimbaud, Constance de Margerie, Samia Mourah, Raphael Porcher, Martine Bagot, Anne Janin, Eric de Kerviler, Celeste Lebbe
Journal: Journal of Clinical Oncology (2014)

e20026 Background: Fine-needle aspiration cytology (FNAC) is used in most of experienced centers to confirm melanoma metastatic spread to the lymph node. In our University Hospital, UltraSound-guided Core Needle Biopsy (US-CNB) is used for all superficial lymph node biopsies. Our objective was to investigate the diagnostic value of US-CNB in the diagnosis of lymph node metastasis in melanoma and compare it to FNAC accuracy in the literature. Methods: All patients with invasive melanoma followed in Saint-Louis Hospital between 2006 and 2010, who underwent a US-CNB for a suspicion of melanoma lymph node metastasis, were retrospectively screened. Histological results of US-CNB samples were diagnosed as melanoma, other malignancy, suspicious, inadequate or benign. The diagnostic accuracy was assessed by comparison with 2 reference standards: histopathological examination of the radical lymph node dissection, or when it was not available, clinical and radiological follow-up. The amount of tissue yielded was evaluated and mutational analysis results were reviewed. Results: The data from 72 patients were analyzed. 44 melanoma, 22 benign, 3 other malignancies, 3 inadequate samples and no inconclusive specimens were diagnosed. 71 US-CNB results were confirmed (98.6%). US-CNB achieved high sensitivity, specificity and PPV (respectively 97.9%, 100 %, and 100 %). No adverse events were reported after the procedure. USGCNB provided a mean tissue volume of 16.7 mm3 per lymphadenopathy allowing to perform complete analysis for BRAF, NRAS and c-KIT mutational status in 10 patients. Conclusions: US-CNB possess similar diagnostic value to FNAC for which sensitivity and specificity values in metastatic melanoma have ranged between 86.5 and 100 %. Recent studies about FNAC demonstrated inconclusive rates ranging from 3.3 to 18.8% whereas our series demonstrated none. US-CNB constitutes a reliable diagnostic method in melanoma lymph node metastasis to avoid surgical procedures in patients who will not benefit from it, and provides large samples of tissue suitable for comprehensive genomic analyses.
Acute Myeloid Leukemia Relapses after Allogenenic HSCT Display a Distinctive Immune-Related Signature, with Frequent and Functionally Relevant Alterations in HLA Class II Antigen Presentation and T Cell Costimulation
Authors: Cristina Toffalori, Michela Riba, Laura Zito, Matteo Barcella, Orietta Spinelli, Lara Crucitti, Nicoletta Cieri, Jacopo Peccatori, Massimo Bernardi, Chiara Bonini, Davide Cittaro, Dejan Lazarevic, Alessandro Rambaldi, Cristina Barlassina, Elia Stupka, Fabio Ciceri, Katharina Fleischhauer, Luca Vago
Journal: Blood (2014)
The role of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases
Authors: Ethel Cesarman, Daniel M. Knowles
Journal: Seminars in Cancer Biology (1999)

The Kaposi's sarcoma-associated herpesvirus (KSHV), also called human herpesvirus 8 (HHV–8), has been found to be present in a limited subset of lymphoproliferative disorders. Among these are the primary effusion lymphomas, formerly designated body cavity-based lymphomas, a rare type of malignant lymphoma which possesses an unusual set of clinical and biologic features, suggesting that they represent a distinct disease entity. This virus is also present in a large proportion of cases of multicentric Castleman's disease, particularly those associated with HIV–infection. In addition, KSHV has been implicated in the pathogenesis of multiple myeloma, where it has been identified in bone marrow adherent cells but not in the neoplastic myeloma plasma cell population. However, the latter finding remains controversial. The discovery of KSHV in a subset of malignant lymphomas has allowed the development of lymphoma cell lines which now serve as biological reagents for propagating the virus, as a substrate for serologic assays, and as a model system for pathobiologic studies. This review discusses the features of KSHV–associated lymphoproliferative disorders and the evidence supporting its role in the pathogenesis of these diseases.
Laid Off
Authors: M Therese Southgate
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 14017: Contemporary Management Strategies Provide Low Mortality Rates for Young Patients with Hypertrophic Cardiomyopathy
Authors: Ethan J Rowin, Martin S Maron, Susan A Casey, John R Lesser, Ross F Garberich, Mark S Link, Barry J Maron
Journal: Circulation (2014)

Background: Historically, youthful age has been considered the time period of greatest risk for patients with hypertrophic cardiomyopathy (HCM), largely a consequence of increased risk of sudden cardiac death. However, the last two decades have witnessed emergence of an expanded risk stratification algorithm resulting in more reliable identification of at-risk patients and enhanced utilization of implantable cardioverter-defibrillators (ICD) for sudden death prevention. However, whether these advances have significantly altered mortality rates for young HCM patients is currently unresolved. Objective: Define the clinical course and adverse event rate in children and young adults with HCM. Methods: We studied the long-term outcomes of 321 consecutive HCM patients presenting at 2 institutions between 10 and 29 years of age, and followed over 7.2 ± 4.8 years. Results: Over follow-up, 302 patients (94%) survived to 27 ± 5 years, with the majority (96%) experiencing no or mild symptoms at last evaluation. HCM-related death occurred in 16 patients (5%; 0.7%/year): arrhythmic sudden death (n=12), complications following heart transplant (n=3), and progressive heart failure (n=1). In contrast, aborted HCM-related mortality occurred in 41 other high-risk HCM patients (implantable cardioverter-defibrillator (ICD) interventions for ventricular tachyarrhythmia [n =24], resuscitated out of hospital cardiac arrest [n=7], and heart transplant for advanced unrelenting heart failure [n=10]), 2.0%/year, and at a rate almost 3-fold higher than actual HCM mortality. Survival at 5- and 10-years (considering only HCM deaths) was excellent at 97% and 92%, and not significantly different from survival rates recently reported in HCM patients identified during mid-life (ages 30 to 59 years old; 98% and 94%, p=0.23). Conclusions: In a cohort of young HCM patients contemporary treatment strategies have resulted in low mortality (&lt;1%/year), due largely to identification of high-risk patients who benefit from sudden death prevention with the ICD, creating the opportunity for extended longevity.
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant<i>IDH</i>glioma patients
Authors: Kourosh Jafari-Khouzani, Franziska Loebel, Wolfgang Bogner, Otto Rapalino, Gilberto R. Gonzalez, Elizabeth Gerstner, Andrew S. Chi, Tracy T. Batchelor, Bruce R. Rosen, Jan Unkelbach, Helen A. Shih, Daniel P. Cahill, Ovidiu C. Andronesi
Journal: Neuro-Oncology (2016)

Gliomas with mutant isocitrate dehydrogenase (IDH) produce high levels of 2-hydroxyglutarate (2HG) that can be quantitatively measured by 3D magnetic resonance spectroscopic imaging (MRSI). Current glioma MRI primarily relies upon fluid-attenuated inversion recovery (FLAIR) hyperintensity for treatment planning, although this lacks specificity for tumor cells. Here, we investigated the relationship between 2HG and FLAIR in mutant IDH glioma patients to determine whether 2HG mapping is valuable for radiotherapy planning.Seventeen patients with mutant IDH1 gliomas were imaged by 3 T MRI. A 3D MRSI sequence was employed to specifically image 2HG. FLAIR imaging was performed using standard clinical protocol. Regions of interest (ROIs) were determined for FLAIR and optimally thresholded 2HG hyperintensities. The overlap, displacement, and volumes of 2HG and FLAIR ROIs were calculated.In 8 of 17 (47%) patients, the 2HG volume was larger than FLAIR volume. Across the entire cohort, the mean volume of 2HG was 35.3 cc (range, 5.3-92.7 cc), while the mean volume of FLAIR was 35.8 cc (range, 6.3-140.8 cc). FLAIR and 2HG ROIs had mean overlap of 0.28 (Dice coefficients range, 0.03-0.57) and mean displacement of 12.2 mm (range, 3.2-23.5 mm) between their centers of mass.Our results indicate that for a substantial number of patients, the 2HG volumetric assessment of tumor burden is more extensive than FLAIR volume. In addition, there is only partial overlap and asymmetric displacement between the centers of FLAIR and 2HG ROIs. These results may have important implications for radiotherapy planning of IDH mutant glioma.
춘계학술대회 : 구연 ; 인체의 다단계 간암발생과정에서 Telomere Binding Protein인 TRF1, TRF2 및 TIN2의 발현증가와 Telomere 길이 감소의 상관관계
Authors: 박영년, 오봉경, 김영주, 박찬일
Journal: Clinical and Molecular Hepatology (2005)

Background: Telomere shortening is important for carcinogenesis and the telomeric repeat binding factor 1 (TRF1), TRF2 and the TRF1-interacting nuclear protein 2 (TIN2) are involved in telomere maintenance. We describe the regulation of expression of thes
Case 52-1977
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Richard M. Friedenberg, Robert E. Scully
Journal: New England Journal of Medicine (1977)

Presentation of CaseA 66-year-old woman was admitted to the hospital because of a mass in the right upper quadrant of the abdomen.The patient had a history of congenital dislocation of the hips with degenerative joint disease. Fifteen months before admission bilateral total-hip replacement was performed. Three weeks later hematuria and a urinary-tract infection developed; an intravenous pyelographic examination was negative. A stool specimen gave a ++ test for occult blood, but she declined further evaluation.Six months before admission a barium-enema examination disclosed a colonic tumor. Resection of the sigmoid colon was performed; microscopical examination showed a well . . .
Cardiovascular Events in a Physical Activity Intervention Compared With a Successful Aging Intervention
Authors: Anne B. Newman, John A. Dodson, Timothy S. Church, Thomas W. Buford, Roger A. Fielding, Stephen Kritchevsky, Daniel Beavers, Marco Pahor, Randall S. Stafford, Anita D. Szady, Walter T. Ambrosius, Mary M. McDermott
Journal: JAMA Cardiology (2016)

Whether sustained physical activity prevents cardiovascular disease (CVD) events in older adults is uncertain.To test the hypothesis that cardiovascular morbidity and mortality would be reduced in participants in a long-term physical activity program.The Lifestyle Interventions and Independence for Elders (LIFE) study was a multicenter, randomized trial. Participants were recruited at 8 centers in the United States. We randomized 1635 sedentary men and women aged 70 to 89 years with a Short Physical Performance Battery (SPPB) score of 9 or less but able to walk 400 m.The physcial activity (PA) intervention was a structured moderate-intensity program, predominantly walking 2 times per week on site for 2.6 years on average. The successful aging intervention consisted of weekly health education sessions for 6 months, then monthly.Total CVD events, including fatal and nonfatal myocardial infarction, angina, stroke, transient ischemic attack, and peripheral artery disease, were adjudicated by committee, and silent myocardial infarction was assessed by serial electrocardiograms. A limited outcome of myocardial infarction, stroke, and CVD death was also studied. Outcome assessors and adjudicators were blinded to intervention assignment.The 1635 LIFE study participants were predominantly women (67%), with a mean (SD) age of 78.7 (5.2) years; 20% were African-American, 6% were Hispanic or other race or ethnic group, and 74% were non-Latino white. New CVD events occurred in 121 of 818 PA participants (14.8%) and 113 of 817 successful aging participants (13.8%) (HR, 1.10; 95% CI, 0.85-1.42). For the more focused combined outcome of myocardial infarction, stroke, or cardiovascular death, rates were 4.6% in PA and 4.5% in the successful aging group (HR, 1.05; 95% CI, 0.67-1.66). Among frailer participants with an SPPB score less than 8, total CVD rates were 14.2% in PA vs 17.7% in successful aging (HR, 0.76; 95% CI, 0.52-1.10), compared with 15.3% vs 10.5% among those with an SPPB score of 8 or 9 (HR, 1.59; 95% CI, 1.09-2.30) (P for interaction = .006). With the limited end point, the interaction was not significant (P = .59), with an HR of 0.94 (95% CI, 0.50-1.75) for an SPPB score less than 8 and an HR of 1.20 (95% CI, 0.62-2.34) for an SBBP score of 8 or 9.Among participants in the LIFE Study, an aerobically based, moderately intensive PA program was not associated with reduced cardiovascular events in spite of the intervention's previously documented ability to prevent mobility disability.clinicaltrials.gov Identifier: NCT00116194.
INTESTINAL PARASITES AS A FREQUENT CAUSE OF UNDIAGNOSED MALADIES IN CHILDREN
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016
Authors: Emi Takashita, Seiichiro Fujisaki, Masayuki Shirakura, Kazuya Nakamura, Noriko Kishida, Tomoko Kuwahara, Yukie Shimazu, Takeshi Shimomura, Shinji Watanabe, Takato Odagiri
Journal: Eurosurveillance (2016)

An influenza A(H1N1)pdm09 virus carrying a G147R substitution in combination with an H275Y substitution in the neuraminidase protein, which confers cross-resistance to oseltamivir and peramivir, was detected from an immunocompromised inpatient in Japan, March 2016. This dual H275Y/G147R mutant virus exhibited enhanced cross-resistance to both drugs compared with the single H275Y mutant virus and reduced susceptibility to zanamivir, although it showed normal inhibition by laninamivir.
Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study
Authors: T. Boch, B. Spiess, O.A. Cornely, J.J. Vehreschild, P.M. Rath, J. Steinmann, W.J. Heinz, J. Hahn, S.W. Krause, M.G. Kiehl, G. Egerer, T. Liebregts, M. Koldehoff, M. Klein, F. Nolte, M.C. Mueller, N. Merker, S. Will, M. Mossner, H. Popp, W.-K. Hofmann, M. Reinwald, D. Buchheidt
Journal: Clinical Microbiology and Infection (2016)
Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.
Authors: Peter A. Fasching, Guy Heinrich Maria Jerusalem, Xavier Pivot, Miguel Martin, Michele De Laurentiis, Kimberly L. Blackwell, Francisco J. Esteva, Stephen K. L. Chia, Caroline Germa, Zhongwen Tang, Shyeilla V. Dhuria, Dennis J. Slamon
Journal: Journal of Clinical Oncology (2016)

TPS624 Background: Inhibition of the cyclin D–cyclin dependent kinase (CDK)4/6–retinoblastoma pathway may overcome ET resistance and enhance the efficacy of existing ET regimens in HR+, HER2– aBC. Combination of the CDK4/6 inhibitor ribociclib (LEE) with fulvestrant (FUL) has demonstrated potent tumor regressions in preclinical HR+ breast cancer (BC) models (O’Brien et al. Cancer Res 2014;74:Abstr 4756). Methods: In this phase III, double-blind study (NCT02422615), postmenopausal patients with HR+, HER2– aBC (N≈660) will be randomized 2:1 to oral LEE (600 mg QD on Days 1–21 of each 28-day cycle) + FUL (500 mg intramuscularly on Days 1 and 15 of Cycle 1 and Day 1 of each cycle thereafter; Arm A) or placebo + FUL (Arm B). Randomization is stratified by presence of lung or liver metastases and prior ET. Patients may have newly diagnosed aBC that is treatment-naïve, relapsed BC that has progressed at any time during/after (neo)adjuvant ET with no treatment for metastatic disease, relapsed BC that has progressed > 12 months after adjuvant ET and then subsequently progressed after 1 line of ET for metastatic disease, or newly diagnosed aBC that has progressed after 1 line of ET. Patients must have measurable disease or ≥ 1 predominantly lytic bone lesion, and an Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤ 1. Prior chemotherapy (except for [neo]adjuvant chemotherapy), FUL, or any CDK4/6 inhibitor is prohibited. Tumor assessments occur every 8 weeks for the first 18 months and every 12 weeks thereafter until disease progression or study discontinuation. The primary endpoint is progression-free survival (PFS; local, RECIST v1.1). Secondary endpoints include overall survival, PFS (central, RECIST 1.1), overall response rate, clinical benefit rate, time to response, duration of response, safety and tolerability, time to deterioration of ECOG PS, patient-reported outcomes, and pharmacokinetics. Exploratory endpoints include molecular alterations in tumor biopsy and circulating tumor DNA. Clinical trial information: NCT02422615.
Case 14-1963
Authors: Paul S. Russell, Benjamin Castleman
Journal: New England Journal of Medicine (1963)

Presentation of CaseA thirty-six-year-old woman was referred to the hospital for treatment of arthritic deformities of the hips.Six years before entry the patient had the onset of joint pain, swelling and stiffness of the hands. Subsequently, similar involvement of the knees, ankles, hips, elbows and shoulders caused progressive disability. She was treated with triamcinolone, prednisone and salicylates, and during the two years before admission she was maintained on prednisone, 15 mg. per day. A course of gold therapy was given three years before entry, followed by a daily maintenance dose of 25 mg. per mouth until one month . . .
P-154 Combined oxaliplatin, irinotecan and fluorouracil as a rescue regimen for heavily pretreated metastatic colorectal cancer patients
Authors: G. Dos Santos Fernandes, M.I. Braghiroli, M. Artioli, C. Paterlini Ana, M.C. Teixeira, B. Gumz, F. Costa, P. Hoff
Journal: Annals of Oncology (2016)
Extreme Thrombocytosis Under Azacitidine in Patients with Myelodysplastic Syndrome
Authors: Charikleia Kelaidi, Dimitrios Kokkinidis, Maria Protopappa, Georgios Papaioannou, Ioannis Batsis, Chrysa Apostolou, Kostas Stamatopoulos, Anastasia Athanasiadou, Achilles Anagnostopoulos, Chrysanthi Vadikoliou
Journal: Blood (2012)